Session

IBD (Posters)

COMPARATIVE ASSESSMENT C-REACTIVE PROTEIN BETWEEN A POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (IMMUNONEPHELOMETRIC TESTING)
COMPARATIVE ASSESSMENT C-REACTIVE PROTEIN BETWEEN A POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (IMMUNONEPHELOMETRIC TESTING)

ROLE OF NOTCH PATHWAY IN CROHN'S DISEASE: IMPLICATIONS IN FIBROSIS
ROLE OF NOTCH PATHWAY IN CROHN'S DISEASE: IMPLICATIONS IN FIBROSIS

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL

INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITH RESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN'S DISEASE
INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITH RESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN'S DISEASE

TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE
TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE

MUCUS COMPOSITION ALTERATIONS IN INFLAMMATORY BOWEL DISEASES (IBD)
MUCUS COMPOSITION ALTERATIONS IN INFLAMMATORY BOWEL DISEASES (IBD)

DE-ESCALATION OF BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS FOLLOWING PRIOR ESCALATION
DE-ESCALATION OF BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS FOLLOWING PRIOR ESCALATION

REAL-WORLD IMPACT OF BIOLOGICAL THERAPIES ON WORK IMPAIRMENT AND QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE PATIENTS
REAL-WORLD IMPACT OF BIOLOGICAL THERAPIES ON WORK IMPAIRMENT AND QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE PATIENTS

MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN'S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY
BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN'S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY

UNTARGETED SERUM METABOLOME IN LONGITUDINAL CROHN'S DISEASE (CD) COHORT ENROLLED DURING REMISSION SHOWS STRONG INDIVIDUALIZED SIGNATURE AND CD-ASSOCIATED SIGNALS THAT ARE MAINTAINED ALSO IN PATIENTS WHO NORMALIZED THEIR FECAL CALPROTECTIN
UNTARGETED SERUM METABOLOME IN LONGITUDINAL CROHN'S DISEASE (CD) COHORT ENROLLED DURING REMISSION SHOWS STRONG INDIVIDUALIZED SIGNATURE AND CD-ASSOCIATED SIGNALS THAT ARE MAINTAINED ALSO IN PATIENTS WHO NORMALIZED THEIR FECAL CALPROTECTIN

SERUM LEVELS OF INFLIXIMAB AND ADALIMUMAB BIOSIMILARS CAN BE MEASURED EQUIVALENTLY TO ORIGINATOR DRUGS BY QUANTUM BLUE RAPID TESTING AS TOOL FOR THERAPEUTIC DRUG MONITORING
SERUM LEVELS OF INFLIXIMAB AND ADALIMUMAB BIOSIMILARS CAN BE MEASURED EQUIVALENTLY TO ORIGINATOR DRUGS BY QUANTUM BLUE RAPID TESTING AS TOOL FOR THERAPEUTIC DRUG MONITORING

SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

THE IBD DISK IS WELL CORRELATED WITH ENDOSCOPIC AND BIOMARKER EVIDENCE OF INFLAMMATION IN CROHN'S DISEASE PATIENTS
THE IBD DISK IS WELL CORRELATED WITH ENDOSCOPIC AND BIOMARKER EVIDENCE OF INFLAMMATION IN CROHN'S DISEASE PATIENTS

HUMAN INTESTINAL EPITHELIAL CELLS INTERNALIZE LUMINAL FUNGI VIA LC3-ASSOCIATED PHAGOCYTOSIS
HUMAN INTESTINAL EPITHELIAL CELLS INTERNALIZE LUMINAL FUNGI VIA LC3-ASSOCIATED PHAGOCYTOSIS

COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL
COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL

ANTIOXIDANT VITAMINS AND ELECTROLYTES INCREASED INTAKE IS ASSOCIATED WITH LOWER DISEASE ACTIVITY AND BETTER QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
ANTIOXIDANT VITAMINS AND ELECTROLYTES INCREASED INTAKE IS ASSOCIATED WITH LOWER DISEASE ACTIVITY AND BETTER QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

PHARMACOKINETIC AND NONCLINICAL SAFETY EVALUATION OF SZN-1326, A WNT SIGNAL ACTIVATOR, IN NON-HUMAN PRIMATES
PHARMACOKINETIC AND NONCLINICAL SAFETY EVALUATION OF SZN-1326, A WNT SIGNAL ACTIVATOR, IN NON-HUMAN PRIMATES

ELEVATED FECAL CALPROTECTIN IS GOOD INDICATOR OF PERSISTENT HISTOLOGICAL ACTIVITY DESPITE ENDOSCOPIC REMISSION IN UC PATIENTS TREATED WITH BIOLOGICS
ELEVATED FECAL CALPROTECTIN IS GOOD INDICATOR OF PERSISTENT HISTOLOGICAL ACTIVITY DESPITE ENDOSCOPIC REMISSION IN UC PATIENTS TREATED WITH BIOLOGICS

Item 101 - 120 / 567
1 2 3 4 5
6
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29